Cryo-Cell International Receives NYSE Compliance Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy CCEL?
Source: seekingalpha
- Compliance Warning: Cryo-Cell International has received a notice from NYSE American indicating non-compliance due to stockholder deficit as of November 30, 2025, and net losses in two of the last three fiscal years, which could jeopardize its listing status.
- Financial Condition Analysis: The notice highlights financial challenges faced by Cryo-Cell in fiscal years 2023, 2024, and 2025, particularly the existence of stockholder deficits, indicating pressure on the company's profitability and financial health.
- Compliance Plan Submission: Cryo-Cell plans to submit a compliance plan to the exchange, and if accepted, the company could have up to 18 months to regain compliance, providing a buffer period to improve its financial situation.
- Trading Impact: Despite the warning, Cryo-Cell emphasizes that the notice has no immediate effect on the listing or trading of its common stock, indicating that the company is actively managing its market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CCEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CCEL
About CCEL
Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cryo-Cell International Receives NYSE Compliance Notice
- Compliance Warning: Cryo-Cell International has received a notice from NYSE American indicating non-compliance due to stockholder deficit as of November 30, 2025, and net losses in two of the last three fiscal years, which could jeopardize its listing status.
- Financial Condition Analysis: The notice highlights financial challenges faced by Cryo-Cell in fiscal years 2023, 2024, and 2025, particularly the existence of stockholder deficits, indicating pressure on the company's profitability and financial health.
- Compliance Plan Submission: Cryo-Cell plans to submit a compliance plan to the exchange, and if accepted, the company could have up to 18 months to regain compliance, providing a buffer period to improve its financial situation.
- Trading Impact: Despite the warning, Cryo-Cell emphasizes that the notice has no immediate effect on the listing or trading of its common stock, indicating that the company is actively managing its market position.
See More
Cryo-Cell International Reports Fiscal 2025 Results
- Revenue Decline: Cryo-Cell International reported consolidated revenues of $31.6 million for fiscal 2025, down from $32.0 million in fiscal 2024, primarily due to a decrease in public banking revenue, indicating signs of weakened market demand that could impact future cash flows.
- Increased Net Loss: The company reported a net loss of $2.4 million for fiscal 2025, translating to a loss of $0.30 per share, compared to a net income of $402,000 in fiscal 2024, highlighting increased operational pressures that necessitate measures to improve financial health.
- Impairment Charge Impact: An impairment charge of $4.4 million was recognized in Q4 2025 due to changes in sales trends and estimated recoverability of inventory, reflecting challenges in inventory management and market adaptability that may affect investor confidence.
- Strong Market Position: Despite financial challenges, Cryo-Cell remains the world's first private cord blood bank, having served over 500,000 parents and partnering with Duke University for its public banking program, thereby continuing to solidify its leadership position in the industry.
See More
Cryo-Cell International Reports Fiscal 2025 Results
- Revenue Decline: Cryo-Cell International reported consolidated revenues of $31.6 million for fiscal 2025, a decrease from $32.0 million in fiscal 2024, primarily due to a drop in processing and storage fee income, indicating increased competitive pressure in the market.
- Widening Net Loss: The company reported a net loss of $2.4 million for fiscal 2025, translating to a loss of $0.30 per share, compared to a net income of $402,000 in fiscal 2024, reflecting a significant deterioration in financial health.
- Impairment Loss Impact: An impairment charge of $4.4 million was recognized in Q4 2025 due to changes in sales trends and inventory recoverability assessments, leading to a substantial reduction in public inventory value and exacerbating financial strain.
- Market Position Challenges: As the world's first private cord blood bank, Cryo-Cell faces competitive pressure from public cord blood banks, necessitating a focus on strengthening core business and product diversification to maintain market share.
See More
CRYO-CELL International Reports FY Earnings Miss
- Earnings Report Disappointment: CRYO-CELL International's FY GAAP EPS of -$0.30 misses expectations by $0.37, indicating pressure on profitability that could undermine investor confidence.
- Slight Revenue Decline: The company reported revenue of $31.6 million, a 1.3% year-over-year decrease, although it slightly beat market expectations by $0.1 million, yet the ongoing revenue decline poses challenges for future growth.
- Market Reaction Analysis: The earnings miss may raise investor concerns about the company's future profitability, leading to increased stock price volatility and affecting the overall market perception of CRYO-CELL.
- Financial Health Status: Despite the slight revenue beat, the persistent losses and declining revenue may prompt management to implement more aggressive strategic adjustments to improve financial health and restore market confidence.
See More
Cryo-Cell International Reports Fiscal 2025 Results
- Revenue Decline: Cryo-Cell International reported consolidated revenues of $31.6 million for fiscal 2025, down from $32.0 million in 2024, primarily due to a decrease in processing and storage fee revenue to $31.4 million, indicating potential market demand weakness that could impact future liquidity.
- Increased Net Loss: The company reported a net loss of $2.4 million for fiscal 2025, translating to a loss of $0.30 per share, compared to a net income of $402,000 in 2024, reflecting significant challenges in sales trends and inventory impairment that may affect investor confidence.
- Impairment Charge: In Q4 of fiscal 2025, the company recognized a $4.4 million impairment charge due to changes in sales trends and estimated recoverability, reducing inventory from cost to net realizable value, highlighting pressures in asset management.
- Market Position: As the world's first private cord blood bank, Cryo-Cell International has over 500,000 clients across 87 countries, and despite facing financial challenges, its leadership in cord blood and tissue stem cell storage remains significant, with potential for recovery through technological innovation and market expansion.
See More
CRYO-CELL INTERNATIONAL REPORTS FY NET LOSS OF USD 2.4 MILLION
Company Overview: Cryo-Cell International is a company specializing in stem cell preservation and related services.
Financial Performance: The company reported a net income of $2.4 million, indicating a positive financial outcome.
See More
Cryo-Cell International Receives NYSE Compliance Notice
- Compliance Warning: Cryo-Cell International has received a notice from NYSE American indicating non-compliance due to stockholder deficit as of November 30, 2025, and net losses in two of the last three fiscal years, which could jeopardize its listing status.
- Financial Condition Analysis: The notice highlights financial challenges faced by Cryo-Cell in fiscal years 2023, 2024, and 2025, particularly the existence of stockholder deficits, indicating pressure on the company's profitability and financial health.
- Compliance Plan Submission: Cryo-Cell plans to submit a compliance plan to the exchange, and if accepted, the company could have up to 18 months to regain compliance, providing a buffer period to improve its financial situation.
- Trading Impact: Despite the warning, Cryo-Cell emphasizes that the notice has no immediate effect on the listing or trading of its common stock, indicating that the company is actively managing its market position.
See More
Cryo-Cell International Reports Fiscal 2025 Results
- Revenue Decline: Cryo-Cell International reported consolidated revenues of $31.6 million for fiscal 2025, down from $32.0 million in fiscal 2024, primarily due to a decrease in public banking revenue, indicating signs of weakened market demand that could impact future cash flows.
- Increased Net Loss: The company reported a net loss of $2.4 million for fiscal 2025, translating to a loss of $0.30 per share, compared to a net income of $402,000 in fiscal 2024, highlighting increased operational pressures that necessitate measures to improve financial health.
- Impairment Charge Impact: An impairment charge of $4.4 million was recognized in Q4 2025 due to changes in sales trends and estimated recoverability of inventory, reflecting challenges in inventory management and market adaptability that may affect investor confidence.
- Strong Market Position: Despite financial challenges, Cryo-Cell remains the world's first private cord blood bank, having served over 500,000 parents and partnering with Duke University for its public banking program, thereby continuing to solidify its leadership position in the industry.
See More
Cryo-Cell International Reports Fiscal 2025 Results
- Revenue Decline: Cryo-Cell International reported consolidated revenues of $31.6 million for fiscal 2025, a decrease from $32.0 million in fiscal 2024, primarily due to a drop in processing and storage fee income, indicating increased competitive pressure in the market.
- Widening Net Loss: The company reported a net loss of $2.4 million for fiscal 2025, translating to a loss of $0.30 per share, compared to a net income of $402,000 in fiscal 2024, reflecting a significant deterioration in financial health.
- Impairment Loss Impact: An impairment charge of $4.4 million was recognized in Q4 2025 due to changes in sales trends and inventory recoverability assessments, leading to a substantial reduction in public inventory value and exacerbating financial strain.
- Market Position Challenges: As the world's first private cord blood bank, Cryo-Cell faces competitive pressure from public cord blood banks, necessitating a focus on strengthening core business and product diversification to maintain market share.
See More
CRYO-CELL International Reports FY Earnings Miss
- Earnings Report Disappointment: CRYO-CELL International's FY GAAP EPS of -$0.30 misses expectations by $0.37, indicating pressure on profitability that could undermine investor confidence.
- Slight Revenue Decline: The company reported revenue of $31.6 million, a 1.3% year-over-year decrease, although it slightly beat market expectations by $0.1 million, yet the ongoing revenue decline poses challenges for future growth.
- Market Reaction Analysis: The earnings miss may raise investor concerns about the company's future profitability, leading to increased stock price volatility and affecting the overall market perception of CRYO-CELL.
- Financial Health Status: Despite the slight revenue beat, the persistent losses and declining revenue may prompt management to implement more aggressive strategic adjustments to improve financial health and restore market confidence.
See More
Cryo-Cell International Reports Fiscal 2025 Results
- Revenue Decline: Cryo-Cell International reported consolidated revenues of $31.6 million for fiscal 2025, down from $32.0 million in 2024, primarily due to a decrease in processing and storage fee revenue to $31.4 million, indicating potential market demand weakness that could impact future liquidity.
- Increased Net Loss: The company reported a net loss of $2.4 million for fiscal 2025, translating to a loss of $0.30 per share, compared to a net income of $402,000 in 2024, reflecting significant challenges in sales trends and inventory impairment that may affect investor confidence.
- Impairment Charge: In Q4 of fiscal 2025, the company recognized a $4.4 million impairment charge due to changes in sales trends and estimated recoverability, reducing inventory from cost to net realizable value, highlighting pressures in asset management.
- Market Position: As the world's first private cord blood bank, Cryo-Cell International has over 500,000 clients across 87 countries, and despite facing financial challenges, its leadership in cord blood and tissue stem cell storage remains significant, with potential for recovery through technological innovation and market expansion.
See More
CRYO-CELL INTERNATIONAL REPORTS FY NET LOSS OF USD 2.4 MILLION
Company Overview: Cryo-Cell International is a company specializing in stem cell preservation and related services.
Financial Performance: The company reported a net income of $2.4 million, indicating a positive financial outcome.
See More
